|
|
 |
|
Viewing report
|
|
|
|
OTC Obesity in USA
Euromonitor International, March 2010, Pages: 47
Sales of OTC obesity treatments declined by 2% in 2009. The switch of Alli, the first FDA approved weight loss drug, is proving to be a disappointment for GlaxoSmithKline, despite the state of the US population that is ripe for a scientifically tested weight loss remedy. According to the Center for Disease Control, obesity rates increased in 37 US states in 2007 over the previous year. While overall US obesity rates appear to be stabilising, 34% of US adults aged 20 or above were obese in 2006.
The OTC Obesity Products in USA report offers a comprehensive guide to the size and shape of the market at a national level. It provides the latest retail sales data 2005-2009, allowing you to identify the sectors driving growth. Forecasts to 2014 illustrate how the market is set to change.
Product coverage:
Data coverage: market sizes (historic and forecasts), company shares, brand shares and distribution data.
Why buy this report?
- Get a detailed picture of the Consumer Health industry;
- Pinpoint growth sectors and identify factors driving change;
- Understand the competitive environment, the market’s major players and leading brands;
- Use five-year forecasts to assess how the market is predicted to develop.
.
Customers who bought this item also bought
Slimming Products in USA
Analgesics in USA
Emergency Contraception in USA
Digestive Remedies - USA
Vitamins and Dietary Supplements - USA
Analgesics - USA
NRT Smoking Cessation Aids - USA
Cough, Cold and Allergy (hay Fever) Remedies in USA
Vitamins and Dietary Supplements in USA
Digestive Remedies in USA
|
|
|
|
